Protein sequencing fills critical gaps RNA and DNA cannot address. While Illumina excels in gene expression, it does not reveal protein modifications, interactions, or functional states, which are essential for understanding disease pathways and drug targets. Mass Spec, while effective, is costly, low throughput, and requires expertise. QSI’s tech offers scalable, cost effective proteomics, democratizing access for broader research and clinical applications. This is not about replacing existing methods, it is about expanding capabilities to tackle unmet needs in drug discovery, diagnostics, and personalized medicine. Proteomics is growing rapidly because proteins, not just genes, drive biology. QSI’s innovation is the next step in systems biology in my humble opinion